Biogen Idec/PDL BioPharma Plan To Study Daclizumab As Monotherapy For MS
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II monotherapy trial for the monoclonal antibody will initiate in the second half of 2007, PDL tells “The Pink Sheet” DAILY.
You may also be interested in...
Biogen Idec/PDL BioPharma Present Daclizumab CHOICE Data At ECTRIMS
Firms plan to initiate a monotherapy Phase II trial in relapsing MS patients by the end of 2007.
Biogen Idec/PDL BioPharma Present Daclizumab CHOICE Data At ECTRIMS
Firms plan to initiate a monotherapy Phase II trial in relapsing MS patients by the end of 2007.
PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug
A more complicated partnership involving two clinical programs is taking more time to complete than a “ularitide-only” deal, the biotech says.